Alzheimer's Disease Market Research Reports & Industry Analysis
A gradual loss of neurons later in adulthood does not result in significant alteration in brain function during the usual life span. However, the older one gets, the greater the neurologic impairment. Excessive neuronal degeneration in adulthood is called Alzheimer’s disease or senile dementia and is distinguished from the normal changes in aging. Alzheimer’s disease is a progressive disease which results in death of the brain cells causing memory lapses, behavioral issues, and disruption of thinking processes. The disease is considered fatal. Age and generic inheritance are the two key risk factors for developing Alzheimer’s disease. These are also risk factors that are not preventable. However, other preventable risk factors have been linked to the development of AD, including environment, diet, and overall general health. A combination of risk factors is often responsible for the disease.
Alzheimer’s disease is estimated to affect up to 6% of the population over 65. Life expectancy has been increasing around the world due to advances in healthcare, medical research, sanitation, and nutrition. This provides a setting for a higher number of Alzheimer’s disease patients in the future as the population continues to add years to their life.
Alzheimer's Disease Industry Research & Market Reports
-
Vocal Biomarkers Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Type (Frequency, Amplitude, Error Rate, Vocal Rise/Fall Time, Phonation Time, Voice Tremor, Pitch); By Indications (Depression, Attention Deficit, Disruptive Behavior Disorders); By Neurological Disorders (Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, Respiratory & Cardiovascular Disorders, Traumatic Brain Injury); By End User (Hospitals & Clinics, Academic & Research); By Region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America)
... Behavior Disorders); By Neurological Disorders (Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, Respiratory & Cardiovascular Disorders, Traumatic Brain Injury); By End User (Hospitals & Clinics, Academic & Research); By Region (North America, Europe, Asia Pacific, Middle ... Read More
-
Alzheimer's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis 2023-2028
... prevalence of Alzheimer's disease was high in China, followed by U.S. and Japan in 2021. In the 8MM, the total prevalent cases increased from 29,460,996 in 2021 to 36,009,144 cases in 2028. The increasing prevalence ... Read More
-
Blood-Brain Barrier Technologies Market Analysis And Forecast To 2032: By Application (Alzheimer Disease, Epilepsy, Parkinson Disease, Multiple Sclerosis, Hunter Syndrome, Brain Cancer), By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing Permeability, Passive Diffusion, Others), By End-Use (Hospitals, Surgical centers, Research Institutes, Others), And Region
... period. Blood-brain barrier (BBB) is one of the main components of the neurovascular unit and serves as the blood-brain interface to mediate communication between the central nervous system and the periphery. It prevents pathogens and ... Read More
-
Optogenetics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
... a CAGR of 3.86% during 2022-2027. The COVID-19 pandemic is expected to impact the optogenetics market significantly. According to the article published by PUS University in February 2022 by Shanet Suzan Alex, SARS-CoV-2 causes neurological ... Read More
-
Alzheimer’s disease diagnostics and therapeutics Market, by Product (Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others) and Diagnostics (Brain Imaging, CSF Test for Alzheimer’s Disease)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
... East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 Alzheimer’s disease is a neurodegenerative disease that usually starts slowly and progressively worsens. It is a progressive form of dementia, a continuous decline ... Read More
-
Neurotech Devices Market Report 2023-2033
... dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region. Growing Number of Elderly Populations with Neurological Disorders The rapidly growing ... Read More
-
2023 Global: Alzheimer'S Disease Drug - Innovative Markets Forecast (2029) report
... 2018 through 2029. Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2018 to 2029 using regression ... Read More
-
Alzheimer's Disease- Drug Pipeline Landscape, 2023
... gradual decline in memory, thinking, and reasoning skills. Alzheimer's is the most common form of dementia, accounting for 60 to 80 percent of all cases. Dementia is a general term for a decline in mental ... Read More
-
Alzheimer's Drugs Market, Global Forecast 2023-2027, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis
... is a growing brain disorder that, with time, destroys retention and reasoning skills daily. As of know we do not know any reason for the cause Alzheimer disease. Instead, the disease is caused by genetic, ... Read More
-
Alzheimer's Therapeutics Market Report 2022-2032
... dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region. Large Number of Undiagnosed Patient Pool to Propel Growth Residents ... Read More
-
Global Alzheimer’s Therapeutics Market Size, Trends & Growth Opportunity, By Product (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Drug, Pipeline Drugs), By End-user (Hospital Pharmacy, Retail Pharmacy, E-commerce), Forecast till 2027.
... global Alzheimer’s Therapeutics Market was valued at USD 4.20 billion in 2021 which expected to reach USD 15.6 billion by 2027 at a CAGR 16.2% from 2020-2027 Qualiket Market Research covers topics such as worldwide ... Read More
-
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
... Regulatory Path and Key Companies, 2022 Update provides comprehensive information about the Alzheimer pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in ... Read More
-
Alzheimer’s Disease Biomarkers Market (Type of Biomarker: CSF Biomarkers, Genetic Biomarkers, and Blood Biomarkers; and Detection Technique; Molecular Diagnostics and Immunoassays) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
... Market – Scope of Report TMR’s report on the global alzheimer’s disease biomarkers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the ... Read More
-
North America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT),Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and ... Read More
-
Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits ... Read More
-
South & Central America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits ... Read More
-
Europe Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
... and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins ... Read More
-
SARM1 Targeting Therapeutics Market, 2022-2040
... annually. Further, according to a report published by the United Nations (UN), close to 1 billion people, globally, suffer from various types of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and ... Read More
-
Alzheimer’s Disease Diagnostic Market Insights, Competitive Landscape and, Market Forecast - 2027
... GENETIC TESTING, BLOOD BASED TESTS, AND OTHERS), BY END-USER (HOSPITALS & CLINICS, DIAGNOSTIC CENTERS, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST TILL 2027 OWING TO THE INCREASING PREVALENCE ... Read More
-
Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
... to reach USD 9,639.23 million by 2027, registering a CAGR of 5.51% during the forecast period. The emergence of the COVID-19 pandemic had its impact on the Alzheimer’s disease diagnostics and therapeutics market as diagnostic ... Read More
-
Dementia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
... (2022 - 2027). The outbreak of the COVID-19 pandemic is expected to have a considerable impact on the dementia drugs market. According to a study titled, "The effects of the COVID-19 pandemic on people with ... Read More
-
Alzheimer’s Disease Therapeutics (2022 Edition) – Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)
... Analysis has 101 active drugs undergoing several stages of clinical trials. The Alzheimer’s disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer’s disease. Additionally, life ... Read More
-
Global Neurodegenerative Disease Market - 2022-2029
... 7.4% during the forecast period (2022-2029). Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, among others disorders, affect the neurons in the human brain, leading to the inability of neurons to reproduce themselves. Thus, the ... Read More
-
Global X-Ray Detector Market (2022 Edition)– Analysis By Technology, Portability, Application, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028)
... 5246.84 Million in the year 2021. Major factors driving the market growth include increasing demand for early diagnosis and widening scope of clinical applications of X-ray detectors, growing investments in advancing healthcare facilities & digital ... Read More
-
Alzheimer’s Therapeutics Market By Drug Class (Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonist, Others), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
... therapeutics market was valued $6,123 million in 2021 and expected to reach $13017.93 million by 2031, with a CAGR of 8.1% from 2022 to 2031. Alzheimer’s disease is a brain disorder, which slowly destroys memory ... Read More
Research Assistance
